An Australian court has admitted a petition challenging the validity of a patent for a human gene (BRCA1) associated with breast cancer1,2.
The case – filed against the three co-owners of the BRCA1 patent (Myriad Genetics, Centre de recherche du CHUQ and the Cancer Institute) and its exclusive licensee in Australia (Genetic Technologies) – will come up for hearing before the Federal Court of Australia (New South Wales) on 8 July...
Please login to read the full article.
